1-5 of 5
Qian Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-04-12: Optimizing Tolerability of Pyrotinib in HER2-Positive Early-Stage High-Risk Breast Cancer: A Multicenter, Randomized, Three-Cohort Study

Free
Qiao Cheng, Hongyuan Li, Xiaowei Qi, Zhen Zhang, Fuyun Tong, Maoshan Chen, Hai Lei, Lei Xing, Xiang Zhang, Mengyuan Wang, Chao Zhang, Chunyan Li, Qian Wang, Yuxian Wei, Fan Li, Jinxiang Tan, Xuedong Yin, Yixiao Feng, Xiaoyi Wang, Man Huang
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-04-12.
https://doi.org/10.1158/1557-3265.SABCS24-P1-04-12
Published: 13 June 2025
View articletitled, Abstract P1-04-12: Optimizing Tolerability of Pyrotinib in HER2-Positive Early-Stage High-Risk Breast Cancer: A Multicenter, Randomized, Three-Cohort Study
Journal Articles

Mammaglobin: a specific molecular target for immune based breast cancer therapy

Free
Wei Li, Ningxi Zhu, Qian Wang, Timothy P. Fleming, Shaojin You
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B30.
Published: 15 August 2014
View articletitled, Mammaglobin: a specific molecular target for immune based breast cancer therapy
Journal Articles

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Free
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton, Peggy A. Scherle
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7127–7138.
https://doi.org/10.1158/1078-0432.CCR-11-1157
Published: 14 November 2011
View articletitled, A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Open the PDF for A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 in another window
Includes: Supplementary data
Journal Articles

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

Free
Richard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski, Nikhil Ramaiya, Tarsha Huftalen, Nicole Jederlinic, Judith Manola, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 871–879.
https://doi.org/10.1158/1078-0432.CCR-10-2621
Published: 15 February 2011
View articletitled, Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Open the PDF for Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors in another window
Journal Articles

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

Free
Jordan S. Fridman, Eian Caulder, Michael Hansbury, Xiangdong Liu, Genjie Yang, Qian Wang, Yvonne Lo, Bin-Bing Zhou, Maxwell Pan, Sufi M. Thomas, Jennifer R. Grandis, Jincong Zhuo, Wenqing Yao, Robert C. Newton, Steven M. Friedman, Peggy A. Scherle, Kris Vaddi
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1892–1902.
https://doi.org/10.1158/1078-0432.CCR-06-2116
Published: 15 March 2007
View articletitled, Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer
Open the PDF for Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer in another window